Pasar al contenido principal

MODULACION DE LA PROTEINA QUINASA D1 MEDIANTE TERAPIA GENICA COMO NUEVA APROXIMACION TERAPEUTICA PARA LA ESCLEROSIS LATERAL AMIOTROFICA

PID2022-140354OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

  • Moreno-Martinez, Laura
  • Gaja-Capdevila, Núria
  • Mosqueira-Martín, Laura
  • Herrando-Grabulosa, Mireia
  • Rodriguez-Gomez, Laura
  • Gonzalez-Imaz, Klaudia
  • Calvo, Ana C.
  • Sagartzazu-Aizpurua, Maialen
  • Moreno-García, Leticia
  • Fuentes, Jose Manuel
  • Acevedo-Arozena, Abraham
  • Aizpurua, Jesús María
  • Miranda, José Ignacio
  • López de Munain, Adolfo
  • Vallejo-Illarramendi, Ainara
  • Navarro, Xavier
  • Osta, Rosario
  • Gil-Bea, Francisco Javier
Background and Purpose Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target. Experimental Approach A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival. Key Results Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. Conclusions and Implications FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

  • Moreno-Martínez, Laura
  • Gaja-Capdevila, Núria
  • Mosqueira-Martín, Laura
  • Herrando-Grabulosa, Mireia
  • Rodríguez-Gómez, Laura
  • González-Imaz, Klaudia
  • Calvo, Ana C.
  • Sagartzazu-Aizpurua, Maialen
  • Moreno-García, Leticia
  • Fuentes, José Manuel
  • Acevedo-Arozena, Abraham
  • Aizpurua, Jesús M.
  • Miranda, José Ignacio
  • López de Munain, Adolfo
  • Vallejo-Illarramendi, Ainara
  • Navarro, Xavier
  • Osta, Rosario
  • Gil Bea, Francisco Javier
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neu-rodegenerative disease with limited treatment options. ALS pathogenesis involvesintricate processes within motor neurons, characterized by dysregulated Ca 2+ influxand buffering in early ALS-affected motor neurones. This study proposes the modu-lation of ryanodine receptors (RyRs), key mediators of intracellular Ca 2+, as a thera-peutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activityas cytosolic calcium modulators through stabilizing RyR channel activity, weretested in the superoxide dismutase 1 (SOD1) G93A mouse model of ALS. Differentoutcomes were used to assess treatment efficacy, including electrophysiology, his-topathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP-010 was chosen for its centralnervous system availability and favourable in vitro pharmaco-toxicological profile.Chronic administration of MP-010 to SOD1 G93A mice produced preservation ofmotor nerve conduction, with the 61-mg kg 1 dose significantly delaying the onsetof motor impairment. This was accompanied by improved motor coordination,increased innervated endplates and significant preservation of motor neurones inthe spinal cord of treated mice. Notably, MP-010 treatment significantly extendedlifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP-010, exhibit prom-ising neuroprotective effects in ALS, highlighting their potential as novel therapeuticagents. Further investigations into the molecular mechanisms and clinical translat-ability of these compounds are needed for their application in ALS treatment., This work was funded by project CIBER-CALSPI2020/08-1, Grants CB06/05/1105 and CB06/05/0041 from the Instituto de Salud Carlos III of Spain, Grants PID2022-140354OB-I00 and PID2020-119780RB-100 from the Agencia Estatal de Investigación, co-funded by European Union (NextGenerationEU, Recovery, Transformation and Resilience Plan), and Grant IT1732-22 from the Basque Government - Eusko Jaurlaritza. F. J. G.-B. was funded byFundacion Roche Stop Fuga de Cerebros programme (BIO19/ROCHE/017/BD) and received support from the IKERBASQUE, Basque Foundation for Science (IKERBASQUE/PP/2022/003). L. M.-M. holds a PhD fellowship from the Euskal Herriko Univertsitatea (UPV/EHU) (PIF19/184). Open access funding provided by Universidad Pública de Navarra.